| | CBRN Acquisition ActivitiesProject BioShield institutes a secure funding source for the purchase of critical medical countermeasures, such as vaccines, therapeutics, and diagnostics. Project BioShield authorizes $5.6 billion in funding over 10 years for the advanced development and purchase of priority medical countermeasures. The table below represents the Project BioShield procurement activities for medical countermeasures against chemical, biological, radiological and nuclear threats that BARDA is pursuing. Anthrax | Vaccines: recombinant Protective Antigen (rPA) Anthrax Vaccine | Notice Title | Notice Type | Date/Open | Date/Close | RFP-BARDA-08-15: recombinant Protective Antigen (rPA) anthrax vaccine for the strategic national stockpile | Request for Proposal | 12 Feb 2008 | 29 May 2008 | HHS-BARDA-08-01-SB: recombinant protective antigen (rPA) anthrax vaccine for the Strategic National Stockpile | Sources Sought | 8 Feb 2008 | 21 Feb 2008 | SS-DHHS-BARDA-07-01: Anthrax recombinant Protective Antigen (rPA) vaccine for the Strategic National Stockpile (SNS) | Sources Sought | 14 May 07 | 11 June 07 | Acquisition of rPA Anthrax Vaccine for the Strategic National Stockpile | Contract with VaxGen, Inc. Terminated | 19 Sept 2006 | | Award for $877,500,000 to VaxGen, Inc. (Press Release) | 15 Nov 2004 | | RFP-DHHS-ORDC-04-01: Acquisition of Licensed Anthrax Recombinant Protective Antigen (rPA) Vaccine for the Strategic National Stockpile (SNS) | Request for Proposal | 9 Feb 2004 | 16 April 2004 | RFI-ORDC-03-01: Large-Scale Manufacturing Capabilities for Next Generation Anthrax Vaccines (e.g., Anthrax Recombinant Protective Antigen) and Safer Attenuated Vaccinia Vaccines | Request for Information | 12 Aug 2003 | 10 Sept 2003 | Vaccines: Anthrax Vaccine Adsorbed (AVA) | Notice Title | Notice Type | Date/Open | Date/Close | RFP-DHHS-BARDA-08-26: Anthrax Vaccine Adsorbed for the Strategic National Stockpile (SNS) | Award for $404,685,512 to Emergent Biodefense Operations | 30 Sept 2008 | | Presolicitation: Notice of Intent for Sole Source Negotiation | 21 Aug 2008 | 5 Sept 2008 | AVA for the SNS | Award for $447,650,001 to Emergent BioDefense Operations (Press Release) | 25 Sept 2007 | | RFP-DHHS-OPHEMC-VB-07-02: Anthrax Vaccine Adsorbed for the Strategic National Stockpile (SNS) | Sources Sought | 18 April 2007 | 5 June 2007 | 200-2005-11811-01: Purchase of Additional Anthrax Vaccine Adsorbed (AVA) | Contract Modification for $120 million awarded to BioPort Corporation (Press Release) | 5 May 2006 | | Presolicitation: Notice of Intent for Sole Source Negotiation (Press Release) | 3 Nov 2005 | 18 Nov 2005 | 2005-B-01696: Purchase of BioThrax(TM) | Award for $122,737,000 to BioPort Corporation (Press Release) | 5 May 2005 | | Presolicitation: Notice of Intent for Sole Source Negotiation | 4 Nov 2004 | 20 Nov 2004 | Therapeutic Products for Inhalational Anthrax | Notice Title | Notice Type | Date/Open | Date/Close | Acquisition of Therapeutic Products for the Strategic National Stockpile | Option Exercised: Cangene Corporation (Press Release) | 28 July 2006, | | Option Exercised: Human Genome Sciences (Press Release) | 19 June 2006 | | 2004-N-01385: Acquisition of Therapeutic Products for Treatment of Inhalational Anthrax Disease for the Strategic National Stockpile | Award for $1,797,372 to Human Genome Sciences | 12 Oct 2005 | | Award for $422,880 to Cangene Corporation | 12 Oct 2005 | | Request for Proposal | 18 Aug 2004 | | RFI-ORDC-05-04: Anthrax Therapeutics | Request for Information | 22 Feb 2005 | 15 April 2005 |
Other CBRN-Related FBO Announcements: |
|
|
Print 
Download Reader 
